Pierrepont Therapeutics, Inc.
About Pierrepont Therapeutics, Inc.
Pierrepont Therapeutics, Inc. is dedicated to developing targeted treatments for primary mitochondrial diseases and other rare genetic diseases. The company's lead product candidate is PTI-501 (formerly ENTR-501), a proprietary intracellular enzyme replacement therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). The founders have expertise in mitochondrial disease drug development and relationships with key opinion leaders, patient families, and advocacy groups. Pierrepont is focused on a portfolio of treatments for genetically defined Primary Mitochondrial Diseases.
- 🔗 Pierrepont Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 The Mito Fund Makes First Investment in Pierrepont – The Mito Fund: UMDF's Venture Philanthropy Initiative
- 🔗 Pierrepont Therapeutics, Inc.
- 🔗 Pierrepont Therapeutics - Pierrepont Therapeutics is dedicated to developing treatments for primary mitochondrial & other rare genetic diseases.
- 🔗 Peter Barber Email & Phone Number | Pierrepont Therapeutics, Inc. Co-Founder Contact Information
Investors
Key highlights
- Raised $500,000 from The Mito Fund for PTI-501 development.
- Focuses on enzyme replacement therapy for MNGIE and primary mitochondrial diseases.
- Team has experience with multiple approved rare disease treatments.
- Located in Brooklyn, NY with 2-10 employees.
Ask StreetZero about Pierrepont Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account